Holen Sie sich die Stockscreener-App
167.74
0.72%
1.20
Handel nachbörslich:
167.74
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$166.54
Offen:
$166.68
24-Stunden-Volumen:
121.98K
Relative Volume:
0.59
Marktkapitalisierung:
$3.29B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
66.83
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
+4.86%
1M Leistung:
+23.89%
6M Leistung:
+45.53%
1J Leistung:
+63.55%
1-Tages-Spanne:
$166.49
$168.50
1-Wochen-Bereich:
$160.05
$168.50
52-Wochen-Spanne:
$93.58
$168.50
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
167.74 | 3.19B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Is Ligand Pharmaceuticals Incorporated part of any major index2025 Performance Recap & Long-Term Safe Investment Plans - khodrobank.com
Ligand Pharmaceuticals (LGND) director Kozarich sells $76k in stock - Investing.com
Published on: 2025-09-04 06:48:32 - Newser
Custom watchlist performance reports with Ligand Pharmaceuticals Incorporated2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - Newser
Is Ligand Pharmaceuticals Incorporated stock bottoming outTrade Analysis Report & AI Enhanced Trading Signals - Newser
Is Ligand Pharmaceuticals Incorporated stock poised for growthEarnings Recap Summary & Weekly High Return Stock Opportunities - Newser
Using flow based indicators on Ligand Pharmaceuticals IncorporatedMarket Volume Report & Entry Point Confirmation Signals - Newser
Will Ligand Pharmaceuticals Incorporated outperform the market in YEAREarnings Growth Report & Weekly High Potential Stock Alerts - khodrobank.com
Using Python tools to backtest Ligand Pharmaceuticals Incorporated strategiesShare Buyback & Scalable Portfolio Growth Ideas - Newser
What is Ligand Pharmaceuticals Incorporated’s TAM (Total Addressable Market)July 2025 Volume & Capital Protection Trade Alerts - khodrobank.com
Real time pattern detection on Ligand Pharmaceuticals Incorporated stockWeekly Market Outlook & Accurate Technical Buy Alerts - Newser
Advanced analytics toolkit walkthrough for Ligand Pharmaceuticals IncorporatedQuarterly Investment Review & High Conviction Investment Ideas - Newser
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $190 From $167, Maintains Outperform Rating - MarketScreener
Can volume confirm reversal in Ligand Pharmaceuticals Incorporated2025 Support & Resistance & Verified Short-Term Trading Plans - Newser
Custom strategy builders for tracking Ligand Pharmaceuticals IncorporatedJuly 2025 Volume & Comprehensive Market Scan Reports - Newser
Will earnings trigger a reversal in Ligand Pharmaceuticals Incorporated2025 Price Action Summary & Consistent Profit Focused Trading Strategies - Newser
Using data models to predict Ligand Pharmaceuticals Incorporated stock movement2025 Trading Volume Trends & Safe Entry Trade Reports - Newser
Aug Levels: What is the next catalyst for Ligand Pharmaceuticals IncorporatedQuarterly Market Summary & Risk Adjusted Buy/Sell Alerts - khodrobank.com
How to build a dashboard for Ligand Pharmaceuticals Incorporated stockTrade Analysis Summary & Safe Swing Trade Setups - Newser
Is this a good reentry point in Ligand Pharmaceuticals Incorporated2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
Benchmark Reaffirms Buy Rating on Ligand with Raised PT to $175. - AInvest
Volume spikes in Ligand Pharmaceuticals Incorporated stock – what they meanMarket Performance Report & Capital Protection Trading Alerts - Newser
Applying Wyckoff theory to Ligand Pharmaceuticals Incorporated stockMarket Rally & Weekly Market Pulse Updates - Newser
Is Ligand Pharmaceuticals Incorporated attractive for institutional investorsLong Setup & Short-Term Trading Opportunity Alerts - khodrobank.com
Aug Movers: What is Ligand Pharmaceuticals Incorporated s revenue forecastJuly 2025 Catalysts & Weekly Breakout Watchlists - khodrobank.com
Will Ligand Pharmaceuticals Incorporated continue its uptrend2025 Institutional Moves & Accurate Trade Setup Notifications - Newser
Can Ligand Pharmaceuticals Incorporated rally from current levelsProduct Launch & Short-Term Trading Opportunity Alerts - Newser
Heatmap analysis for Ligand Pharmaceuticals Incorporated and competitorsJuly 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Will Ligand Pharmaceuticals Incorporated see short term momentumMarket Rally & Growth Oriented Trade Recommendations - Newser
Using portfolio simulators with Ligand Pharmaceuticals Incorporated includedGDP Growth & Safe Capital Growth Plans - Newser
What to do if you’re stuck in Ligand Pharmaceuticals IncorporatedMarket Risk Analysis & Real-Time Stock Entry Alerts - Newser
Can Ligand Pharmaceuticals Incorporated recover in the next quarter2025 Market WrapUp & High Accuracy Trade Signal Alerts - Newser
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ligand Pharmaceuticals Inc-Aktie (LGND) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KOZARICH JOHN W | Director |
Aug 01 '25 |
Sale |
131.88 |
467 |
61,586 |
45,989 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):